Highlights OSE Immunotherapeutics

Equities

OSE

FR0012127173

Market Closed - Euronext Paris Other stock markets 11:35:07 2024-05-06 am EDT			5-day change	1st Jan Change
6.33 ^EUR	+2.10%		+14.67%	+47.90%

Apr. 17	OSE: licensing agreement with AbbVie enters into force	CF
Apr. 17	OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

OSE: licensing agreement with AbbVie enters into force	Apr. 17	CF
OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie	Apr. 17	MT
OSE Immunotherapeutics SA's Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective	Apr. 16	CI
Global markets live: Airbus, UBS, KKR, Meta Platforms, Tesla...	Apr. 11
Ose Immuno receives funding from Bpifrance	Apr. 11	CF
OSE Immunotherapeutics SA Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
OSE IMMUNOTHERAPEUTICS : Degroof Petercam reiterates buy recommendation	Mar. 18	CF
OSE Immuno: recruitment completed for UC trial	Mar. 18	CF
Ose Immunotherapeutics Sa Announces Completion of Enrollment in Phase 2 Clinical Trial Evaluating Lusvertikimab in Patients with Ulcerative Colitis	Mar. 18	CI
OSE Immuno: share price soars following partnership with AbbVie	Feb. 28	CF
OSE Immunotherapeutics, AbbVie Partner on Chronic Inflammation Monoclonal Antibody	Feb. 28	MT
OSE Immuno: new positive phase 1/2 data	Feb. 27	CF
OSE Immunotherapeutics Provides Update on Clinical Results With OSE-279 in Advanced Solid Tumors	Feb. 26	CI
OSE Immunotherapeutics SA and Nantes University Hospital Presents Positive Interim Data Analysis from the FIRsT Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant	Dec. 11	CI
Ose Immunotherapeutics, GenDx to Co-develop Diagnostic Test Companion for Cancer Vaccine Trial	Nov. 22	MT
OSE Immunotherapeutics SA Announces A Collaboration Agreement with Genome Diagnostics B.V. for the Development of A Companion Diagnostic for Epitope-Based Cancer Vaccine Candidate Tedopi®?	Nov. 21	CI
Ose Immunotherapeutics Sa Announces First Clinical Results for Bi 770371, A Novel Anti-Sirpa Monoclonal Antibody	23-10-23	CI
OSE Immunotherapeutics SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-27	CI
OSE Immunotherapeutics SA Announces Publication in Frontiers in Immunology on Ose-230, Its Novel Agonist Therapy in Chronic Inflammation	23-07-19	CI
OSE Immunotherapeutics and Nantes University Hospital Announce Completion of Patient Enrollment in the FIRsT Clinical Trial, a Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplantation	23-07-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights OSE Immunotherapeutics

Equities

OSE

FR0012127173

Highlights

Filters